These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37560912)
1. Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease. Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Liu K; Jiang Q; Yang T; Xiao Y; Pang D; Zhao B; Chen X; Yang J; Shang H J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2203-2213. PubMed ID: 37560912 [TBL] [Abstract][Full Text] [Related]
3. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
5. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826 [TBL] [Abstract][Full Text] [Related]
6. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q; ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971 [TBL] [Abstract][Full Text] [Related]
7. Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease. Mizutani Y; Ohdake R; Tatebe H; Higashi A; Shima S; Ueda A; Ito M; Tokuda T; Watanabe H J Neurol; 2023 Nov; 270(11):5461-5474. PubMed ID: 37480401 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study. Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029 [TBL] [Abstract][Full Text] [Related]
9. Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease. Zhu SG; Chen ZL; Xiao K; Wang ZW; Lu WB; Liu RP; Huang SS; Zhu JH; Zhang X; Wang JY Eur J Med Res; 2024 Jun; 29(1):334. PubMed ID: 38880878 [TBL] [Abstract][Full Text] [Related]
10. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele. Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425 [TBL] [Abstract][Full Text] [Related]
11. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. Huang Y; Li Y; Xie F; Guo Q CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638 [TBL] [Abstract][Full Text] [Related]
12. Association of plasma phosphor-tau181 with Aβ levels may vary by APOE ε4 status and sex among non-demented old adults. Cai Y; Fu P; Zhang X; Neurosci Lett; 2023 Apr; 802():137161. PubMed ID: 36858305 [TBL] [Abstract][Full Text] [Related]
13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
14. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences. Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K; Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100 [TBL] [Abstract][Full Text] [Related]
15. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513 [TBL] [Abstract][Full Text] [Related]
16. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease. Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288 [TBL] [Abstract][Full Text] [Related]
17. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
18. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967 [TBL] [Abstract][Full Text] [Related]